Displaying 121 - 132 of 136
Metabolism, Alcohol & Toxicity
3

Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021

View
Metabolism, Alcohol & Toxicity
3

Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Displaying 121 - 132 of 136